Investigated and available therapeutic options for treating aceruloplasminemia

Bibliography

• Sipe JC, Lee P, Beutler E. Brain iron metabolism and neurodegenerative disorders. Dev Neurosci 2002;24:188-96
   PubMed Web of Science ®Google Scholar
• Miyajima H, Nishimura Y, Mizoguchi K, et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987;37:761-7
   PubMed Web of Science ®Google Scholar
• Miyajima H, Kono S, Takahashi Y, et al. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002;29:433-8
   PubMed Web of Science ®Google Scholar
• Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-43
   PubMed Web of Science ®Google Scholar
• Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathol 2003;23:345-50
   PubMed Web of Science ®Google Scholar
• Kono S. Aceruloplasminemia. Curr Drug Target 2012;13:1190-9
   PubMed Web of Science ®Google Scholar
• Miyajima H, Kohno S, Takahashi Y, et al. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999;53:617-19
   PubMed Web of Science ®Google Scholar
• Daimon M, Yamatani K, Tominaga M, et al. NIDDM with a ceruloplasmin gene mutation. Diabetes Care 1997;20:678
   PubMed Web of Science ®Google Scholar
• Dunaief JL, Richa C, Franks EP, et al. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmol 2005;112:1062-5
   PubMed Web of Science ®Google Scholar
• Wolkow N, Song Y, Wu TD, et al. Aceruloplasminemia: retinal histopathologic manifestations and iron-mediated melanosome degradation. Arch Ophthalmol 2011;129:1466-74
   PubMed Web of Science ®Google Scholar
• McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008;70:1614-19
   PubMed Web of Science ®Google Scholar
• Mitsumori F, Watanabe H, Takaya N. Estimation of brain iron concentration in vivo using a linear relationship between regional iron and apparent transverse relaxation rate of the tissue water at 4.7T. Magn Reson Med 2009;62:1326-30
   PubMed Web of Science ®Google Scholar
• Miyajima H. Aceruloplasminemia. Neuropathol 2015;35:83-90
   PubMed Web of Science ®Google Scholar
• Hellman NE, Schaefer M, Gehrke S, et al. Hepatic iron overload in aceruloplasminaemia. Gut 2000;47:858-60
   PubMed Web of Science ®Google Scholar
• Kono S, Miyajima H. Aceruloplasminemia. Chapter 45 In: Rosenberg RN, Pascual JM, editors. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. 5th edition. Elsevier, Academic Press, London. 2015;p.495-506
   Google Scholar
• Yang F, Naylor SL, Lum JB, et al. Characterization, mapping, and expression of the human ceruloplasmin gene. Proc Natl Acad Sci USA 1986;83:3257-61
   PubMed Web of Science ®Google Scholar
• Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439-58
   PubMed Web of Science ®Google Scholar
• Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966;241:2746-51
   PubMed Web of Science ®Google Scholar
• Vachette P, Dainese E, Vasyliev VB, et al. A key structural role for active site type 3 copper ions in human ceruloplasmin. J Biol Chem 2002;277:40823-31
   PubMed Web of Science ®Google Scholar
• Patel BN, Dunn RJ, David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 2000;275:4305-10
   Google Scholar
• Shiva S, Wang X, Ringwood LA, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006;2:486-93
   PubMed Web of Science ®Google Scholar
• Samokyszyn VM, Miller DM, Reif DW, et al. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989;264:21-6
   PubMed Web of Science ®Google Scholar
• Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003;278:27144-8
   PubMed Web of Science ®Google Scholar
• Satoh T, Abe K, Nishida Y. Oxidase-like function by apo-transferrin towards Manganese(III) chelates. Int J Chem 2012;4:10-15
   Google Scholar
• Brissot P, Ropert M, Le Lan C, et al. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012;1820:403-10
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kaneko K, Miyajima H, et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 2000;175:91-5
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, di Patti MC, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007;26:2823-31
   PubMed Web of Science ®Google Scholar
• Kono S, Yoshida K, Tomosugi N, et al. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta 2010;1802:968-75
   PubMed Web of Science ®Google Scholar
• Praschberger R, Schranz M, Griffiths WJ, et al. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochim Biophys Acta 2014;1842:1406-12
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Miyajima H, Piperno A, et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010;45:1163-71
   PubMed Web of Science ®Google Scholar
• Guo P, Cui R, Chang YZ, et al. Hepcidin, an antimicrobial peptide is downregulated in ceruloplasmin-deficient mice. Peptides 2009;30:262-6
   PubMed Web of Science ®Google Scholar
• Chasteen ND, Harrison PM. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol 1999;126:182-94
   PubMed Web of Science ®Google Scholar
• Nishida Y. The chemical mechanism of oxidative stress due to the non-transferrin-bound iron (NTBI). Adv Biosci Biotechnol 2012;3:1076-86
   Google Scholar
• Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003;2:246-53
   PubMed Web of Science ®Google Scholar
• Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-73
   PubMed Web of Science ®Google Scholar
• Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci 2003;26:207-14
   PubMed Web of Science ®Google Scholar
• Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 2005;146:1041-59
   PubMed Web of Science ®Google Scholar
• Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995;37:646-56
   PubMed Web of Science ®Google Scholar
• Kawanami T, Kato T, Daimon M, et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatry 1996;61:506-9
   PubMed Web of Science ®Google Scholar
• Xu X, Pin S, Gathinji M, et al. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci 2004;1012:299-305
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cuyar LF, Perry G, Miyajima H, et al. Redox active iron accumulation in aceruloplasminemia. Neuropathol 2008;28:466-71
   PubMed Web of Science ®Google Scholar
• Duce JA, Tsatsanis A, Cater MA, et al. An iron-export ferroxidase activity of beta-amyloid protein precursor is inhibited by zinc in Alzheimer′s Disease. Cell 2010;142:857-67
   PubMed Web of Science ®Google Scholar
• Moos T, Rosengren Nielsen T, Skjørringe T, et al. Iron trafficking inside the brain. J Neurochem 2007;103:1730-40
   PubMed Web of Science ®Google Scholar
• Hahn P, Qian Y, Dentchev T, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA 2004;101:13850-5
   PubMed Web of Science ®Google Scholar
• Jeong SY, David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 2006;26:9810-19
   PubMed Web of Science ®Google Scholar
• Schulz K, Vulpe CD, Harris LZ, et al. Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci 2011;31:13301-11
   PubMed Web of Science ®Google Scholar
• Miyajima H, Takahashi Y, Serizawa M, et al. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Radic Biol Med 1996;20:757-60
   PubMed Web of Science ®Google Scholar
• Miyajima H, Fujimoto M, Kohno S, et al. CSF abnormalities in patients with aceruloplasminemia. Neurology 1998;51:1188-90
   PubMed Web of Science ®Google Scholar
• Miyajima H, Adachi J, Tatsuno Y, et al. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998;50:130-6
   PubMed Web of Science ®Google Scholar
• Kohno S, Miyajima H, Takahashi Y, et al. Defective electron transfer in complexes I and IV in patients with aceruloplasminemia. J Neurol Sci 2000;182:57-60
   PubMed Web of Science ®Google Scholar
• Miyajima H, Adachi J, Kohno S, et al. Increased oxysterols associated with iron accumulation in the brains and visceral organs of acaeruloplasminaemia patients. QJM 2001;94:417-22
   PubMed Web of Science ®Google Scholar
• Miyajima H, Kohno S, Takahashi Y, et al. Zinc concentrations in the tissues of aceruloplasminemia patients. Neurol Therap 2001;18:63-8
   Google Scholar
• Okamoto N, Wada S, Oga T, et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum Genet 1996;97:755-8
   PubMed Web of Science ®Google Scholar
• Miyajima H, Takahashi Y, Kamata T, et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997;41:404-7
   PubMed Web of Science ®Google Scholar
• Pan PL, Tang HH, Chen Q, et al. Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up. Mov Disord 2011;26:2142-4
   PubMed Web of Science ®Google Scholar
• Loreal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002;36:851-6
   PubMed Web of Science ®Google Scholar
• Mariani R, Arosio C, Pelucchi S, et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 2004;53:756-8
   PubMed Web of Science ®Google Scholar
• Yonekawa M, Okabe T, Asamoto Y, et al. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol 1999;42:157-62
   PubMed Web of Science ®Google Scholar
• Hadziahmetovic M, Song Y, Wolkow N, et al. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest Ophthalmol Vis Sci 2011;52:959-68
   PubMed Web of Science ®Google Scholar
• Finkenstedt A, Wolf E, Hofner E, et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 2010;53:1101-7
   PubMed Web of Science ®Google Scholar
• Skidmore FM, Drago V, Foster P, et al. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry 2008;79:467-70
   PubMed Web of Science ®Google Scholar
• Tai M, Matsuhashi N, Ichii O, et al. Case of presymptomatic aceruloplasminemia treated with deferasirox. Hepatol Res 2014;44:1253-8
   PubMed Web of Science ®Google Scholar
• Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. Free Radic Biol Med 2001;31:266-74
   PubMed Web of Science ®Google Scholar
• Mocchegiani E, Bertoni-Freddari C, Marcellini F, et al. Brain, aging and neurodegeneration: role of zinc ion availability. Prog Neurobiol 2005;75:367-90
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-9
   PubMed Web of Science ®Google Scholar
• Klein WL, Stine WBJr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol Aging 2004;25:569-80
   PubMed Web of Science ®Google Scholar
• Sutoh Y, Okawamukai Y, Nishida S, et al. Structure of a new tetranuclear iron(III) complex with an oxo-bridge; factors to govern formation and stability of oxo-bridged iron(III) species in the L-subunit of ferritin. Z Naturforsch C 2006;61:149-54
   PubMed Web of Science ®Google Scholar
• Grabrucker AM, Rowan M, Garner CC. Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 2011;1:13-23
   Google Scholar
• Kuhn J, Bewermeyer H, Miyajima H, et al. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 2007;29:450-3
   PubMed Web of Science ®Google Scholar
• Donangelo CM, Woodhouse LR, King SM, et al. Supplemental zinc lowers measures of iron status in young women with low iron reserves. J Nutr 2002;132:1860-4
   PubMed Web of Science ®Google Scholar
• Hider RC, Ma Y, Molina-Holgado F, et al. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 2008;36:1304-8
   PubMed Web of Science ®Google Scholar
• Vashchenko G, MacGillivray RT. Multi-copper oxidases and human iron metabolism. Nutrients 2013;5:2289-313
   PubMed Web of Science ®Google Scholar